252 related articles for article (PubMed ID: 23687704)
1. [Monitoring of anti-tumour cell-mediated response in patients with renal cell carcinoma, disturbance of T cell proliferation].
Lukesová S; Vroblová V; Hlávková D; Kopecký O; Vokurková D; Morávek P; Safránek H; Soucek P
Vnitr Lek; 2008 Feb; 54(2):139-45. PubMed ID: 23687704
[TBL] [Abstract][Full Text] [Related]
2. Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma.
Kopecký O; Lukesová S; Vroblová V; Vokurková D; Morávek P; Safránek H; Hlávková D; Soucek P
Acta Medica (Hradec Kralove); 2007; 50(3):207-12. PubMed ID: 18254275
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
Kowalczyk D; Skorupski W; Kwias Z; Nowak J
Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
[TBL] [Abstract][Full Text] [Related]
4. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
5. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.
Elsässer-Beile U; Rindsfüser M; Grussenmeyer T; Schultze-Seemann W; Wetterauer U
Br J Cancer; 2000 Sep; 83(5):637-41. PubMed ID: 10944605
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
9. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
[TBL] [Abstract][Full Text] [Related]
10. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
12. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
[TBL] [Abstract][Full Text] [Related]
13. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
[TBL] [Abstract][Full Text] [Related]
14. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma.
Lukesova S; Vroblova V; Tosner J; Kopecky J; Sedlakova I; Čermáková E; Vokurkova D; Kopecky O
Contemp Oncol (Pozn); 2015; 19(4):290-9. PubMed ID: 26557777
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma.
Ning H; Shao QQ; Ding KJ; Gao DX; Lu QL; Cao QW; Niu ZH; Fu Q; Zhang CH; Qu X; Lü JJ
Chin Med J (Engl); 2012 Jun; 125(12):2120-5. PubMed ID: 22884140
[TBL] [Abstract][Full Text] [Related]
17. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
Kim TY; von Eschenbach AC; Filaccio MD; Hayakawa K; Parkinson DR; Balch CM; Itoh K
Cancer Res; 1990 Sep; 50(17):5263-8. PubMed ID: 2143685
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
[TBL] [Abstract][Full Text] [Related]
19. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
20. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.
Liotta F; Gacci M; Frosali F; Querci V; Vittori G; Lapini A; Santarlasci V; Serni S; Cosmi L; Maggi L; Angeli R; Mazzinghi B; Romagnani P; Maggi E; Carini M; Romagnani S; Annunziato F
BJU Int; 2011 May; 107(9):1500-6. PubMed ID: 20735382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]